Literature DB >> 26660146

5th International ACC Symposium: Old Syndromes with New Biomarkers and New Therapies with Old Medications.

Sarika N Rao1, Mouhammed Amir Habra2.   

Abstract

Adrenocortical carcinoma (ACC) is a rare endocrine malignancy with variable but often aggressive clinical course. Hormonal overproduction can be seen in about half of all ACC cases. When present, the hormonal excess leads to a wide range of metabolic, musculoskeletal, cardiovascular, and infectious complications and adds multiple layers of complexity to the management of ACC. To improve the outcome of patients with hormonally functioning ACC, an effective approach should include parallel efforts to achieve oncologic and hormonal control. An experienced multidisciplinary team is crucial to deliver and coordinate care to manage the specific aspects of this condition. In this review, we summarized the clinical features and management of hormonally functioning ACCs to assist practicing physicians in addressing the complex medical issues that can be seen in the context of this clinical entity.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26660146     DOI: 10.1007/s12672-015-0247-9

Source DB:  PubMed          Journal:  Horm Cancer        ISSN: 1868-8497            Impact factor:   3.869


  57 in total

1.  Mortality in Cushing's syndrome: systematic analysis of a large series with prolonged follow-up.

Authors:  G Ntali; A Asimakopoulou; T Siamatras; J Komninos; D Vassiliadi; M Tzanela; S Tsagarakis; A B Grossman; J A H Wass; N Karavitaki
Journal:  Eur J Endocrinol       Date:  2013-10-08       Impact factor: 6.664

Review 2.  Aldosterone-producing adrenocortical carcinoma: an unusual cause of Conn's syndrome with an ominous clinical course.

Authors:  Teresa M Seccia; Ambrogio Fassina; Gastone G Nussdorfer; Achille C Pessina; Gian Paolo Rossi
Journal:  Endocr Relat Cancer       Date:  2005-03       Impact factor: 5.678

3.  Clinical and biological features in the prognosis of adrenocortical cancer: poor outcome of cortisol-secreting tumors in a series of 202 consecutive patients.

Authors:  Gwenaelle Abiven; Joel Coste; Lionel Groussin; Philippe Anract; Frédérique Tissier; Paul Legmann; Bertrand Dousset; Xavier Bertagna; Jérôme Bertherat
Journal:  J Clin Endocrinol Metab       Date:  2006-05-02       Impact factor: 5.958

4.  Feminizing adrenocortical carcinoma in a postmenopausal woman.

Authors:  B Barcelo; J Abascal; J Ardaiz; P Gil; A Colas; J Menendez; J L Inchausti
Journal:  Postgrad Med J       Date:  1979-06       Impact factor: 2.401

5.  Mass spectrometry in the diagnosis of steroid-related disorders and in hypertension research.

Authors:  C H Shackleton
Journal:  J Steroid Biochem Mol Biol       Date:  1993-04       Impact factor: 4.292

Review 6.  A new therapeutic approach in the medical treatment of Cushing's syndrome: glucocorticoid receptor blockade with mifepristone.

Authors:  Maria Fleseriu; Mark E Molitch; Coleman Gross; David E Schteingart; T Brooks Vaughan; Beverly M K Biller
Journal:  Endocr Pract       Date:  2013 Mar-Apr       Impact factor: 3.443

7.  LCI699, a potent 11β-hydroxylase inhibitor, normalizes urinary cortisol in patients with Cushing's disease: results from a multicenter, proof-of-concept study.

Authors:  Xavier Bertagna; Rosario Pivonello; Maria Fleseriu; Yiming Zhang; Paul Robinson; Ann Taylor; Catherine E Watson; Mario Maldonado; Amir H Hamrahian; Marco Boscaro; Beverly M K Biller
Journal:  J Clin Endocrinol Metab       Date:  2013-12-11       Impact factor: 5.958

8.  Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy.

Authors:  J P Luton; S Cerdas; L Billaud; G Thomas; B Guilhaume; X Bertagna; M H Laudat; A Louvel; Y Chapuis; P Blondeau
Journal:  N Engl J Med       Date:  1990-04-26       Impact factor: 91.245

9.  Adrenocortical carcinoma: clinical outcomes and prognosis of 330 patients at a tertiary care center.

Authors:  Montserrat Ayala-Ramirez; Sina Jasim; Lei Feng; Shamim Ejaz; Ferhat Deniz; Naifa Busaidy; Steven G Waguespack; Aung Naing; Kanishka Sircar; Christopher G Wood; Lance Pagliaro; Camilo Jimenez; Rena Vassilopoulou-Sellin; Mouhammed Amir Habra
Journal:  Eur J Endocrinol       Date:  2013-10-23       Impact factor: 6.664

10.  A feminizing adrenocortical carcinoma in the context of a late onset 21-hydroxylase deficiency.

Authors:  Rossella Libé; Wiebke Arlt; Estelle Louiset; Charlotte Waintrop; Jean Guibourdenche; Mathilde Sibony; Eric Clauser; Lionel Groussin
Journal:  J Clin Endocrinol Metab       Date:  2014-03-21       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.